跳至主導覽 跳至搜尋 跳過主要內容

Cotargeting chk1 and pi3k synergistically suppresses tumor growth of oral cavity squamous cell carcinoma in patient-derived xenografts

  • Chia Yu Yang
  • , Chiao Rou Liu
  • , Ian Yi Feng Chang
  • , Chun Nan Ouyang
  • , Chia Hsun Hsieh
  • , Yen Lin Huang
  • , Chun I. Wang
  • , Fei Wen Jan
  • , Wan Ling Wang
  • , Ting Lin Tsai
  • , Hsuan Liu
  • , Ching Ping Tseng
  • , Yu Sun Chang
  • , Chih Ching Wu*
  • , Kai Ping Chang*
  • *此作品的通信作者
  • Chang Gung Memorial Hospital
  • Chang Gung University

研究成果: 期刊稿件 › 文章 › 同儕審查

25 引文 斯高帕斯(Scopus)

摘要

Oral cavity squamous cell carcinomas (OSCCs) are aggressive tumors, and their recurrence leads to poor prognosis and reduced survival rates. This study aimed to identify therapeutic targets and to evaluate the efficacy of targeted inhibitors in OSCC patient-derived xenograft (PDX) models. Herein, we reported that OSCC PDXs recapitulated the genomic signatures of their paired primary tumors and the expression of CHEK1, PIK3CA, and PIK3CD was significantly upregulated in OSCC. The antitumor efficacy of CHK1 inhibitors (PF477736, AZD7762, LY2606368) and PI3K inhibitors (BYL719, GDC0941, GSK1059615) was investigated in OSCC cell lines and PDX models. Targeting either CHK1 or PI3K effectively inhibited cell proliferation and colony formation by inducing cell cycle arrest and apoptosis in in vitro cell-based assays. Cisplatin-based chemotherapy combined with CHK1 inhibitor treatment synergistically inhibited cell proliferation by suppressing CHK1 phosphorylation and inducing PARP cleavage. Furthermore, compared with monotherapy, cotreatment with CHK1 and PI3K inhibitors exerted synergistic anticancer effects by suppressing CHK1, AKT, and 4E-BP1 phosphorylation. In summary, our study identified CHK1 and PI3K as promising targets, especially in a dual treatment strategy combining a CHK1 inhibitor with cisplatin or a PI3K inhibitor as a novel therapeutic approach for OSCC patients with aberrant cell cycle regulation and PI3K signaling activation.

原文英語
文章編號1726
頁(從 - 到)1-20
頁數20
期刊Cancers
卷12
發行號7
DOIs
出版品狀態已出版 - 07 2020

文獻附註

Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.

UN SDG

此研究成果有助於以下永續發展目標

  1. SDG3 健康與福祉
    SDG3 健康與福祉

指紋

深入研究「Cotargeting chk1 and pi3k synergistically suppresses tumor growth of oral cavity squamous cell carcinoma in patient-derived xenografts」主題。共同形成了獨特的指紋。

引用此